Skip to main content
    M

    Moderna Inc (MRNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $215.27
    -8.10 (-3.63%)

    Market Cap: $90.38B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Moderna Inc (MRNA) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Moderna (MRNA) trades at 34.2x sales and 12.6x book value. Its P/S of 34.2x is above its 5-year median of 4.4x. Its forward P/E is 23.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E23.0x
    Price to sales34.2x
    Price to book12.6x
    PEGN/A
    FCF yield-2.3%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S34.2x4.4xN/A
    P/B12.6x2.7xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 8 year ends shown, its P/S ranged from 3.7x in 2022 to 107.8x in 2019.

    Year endPriceP/EP/SP/B
    2025$29.49N/A5.9x1.3x
    2024$41.58N/A4.9x1.5x
    2023$99.45N/A5.6x2.8x
    2022$179.629.0x3.7x3.8x
    2021$253.989.0x5.7x7.7x
    2020$104.47N/A51.3x16.2x
    2019$19.56N/A107.8x5.6x
    2018$15.27N/A39.9x3.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MRNA

    What is MRNA's forward P/E ratio?

    Moderna has a forward P/E ratio of 23.0x.

    Is MRNA stock overvalued?

    GNG's valuation label for MRNA is Overvalued.

    What is MRNA's price to sales ratio?

    Moderna has a price to sales ratio of 34.2x.